Market Currents
More on Jazz Pharmaceuticals (JAZZ): Q2 beats across the board. Total revenues were $129.5M,...
-
Tuesday, August 7, 2012, 4:44 PM ETMore on Jazz Pharmaceuticals (JAZZ): Q2 beats across the board. Total revenues were $129.5M, boosted by strong organic growth and the positive impact of the Azur Pharma and EUSA Pharma acquisitions. The company guided FY12 revenues higher, now expecting revenue of $605M - $615M, versus the current consensus of $599.6M.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
